Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
27-30 April, 2026
Not Confirmed
Not Confirmed
27-30 April, 2026
Bioprocess Internation...Bioprocess International Europe
Not Confirmed
Not Confirmed
27-30 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BPI Europe
Not Confirmed
Contact SupplierBPI Europe
Industry Trade Show
Not Confirmed
27-30 April, 2026
Industry Trade Show
Not Confirmed
27-30 April, 2026
Bioprocess Internation...Bioprocess International Europe
Industry Trade Show
Not Confirmed
27-30 April, 2026
Digital content
NEWS #PharmaBuzz
09 Apr 2026
// PHARMIWEB
https://www.pharmiweb.com/press-release/2026-04-09/sensei-biotherapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference
30 Mar 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260330683907/en/Sensei-Biotherapeutics-Reports-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update
25 Feb 2026
// PHARMIWEB
https://www.pharmiweb.com/press-release/2026-02-25/sensei-biotherapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4
14 Nov 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/sensei-shrinks-workforce-65-warnings-layoffs-come-pass
30 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/30/3177470/0/en/Sensei-Biotherapeutics-Announces-Initiation-of-Strategic-Review-to-Maximize-Shareholder-Value.html
17 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/17/3168569/0/en/Sensei-Biotherapeutics-Reports-New-Clinical-Results-Highlighting-Durable-Progression-Free-Survival-Data-for-Solnerstotug-in-PD-L-1-Resistant-Tumors-at-the-ESMO-Congress-2025.html
Drugs in Development
Details:
Under the acquisition of Serabelisib, the deal aims to advance endometrial cancer treatment by targeting PI3-kinase p110-alpha subunit.
Lead Product(s): Serabelisib,Sapanisertib
Therapeutic Area: Oncology Brand Name: PIKTOR
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: Faeth Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 18, 2026
Lead Product(s) : Serabelisib,Sapanisertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Faeth Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Under the acquisition of Serabelisib, the deal aims to advance endometrial cancer treatment by targeting PI3-kinase p110-alpha subunit.
Product Name : PIKTOR
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 18, 2026
Details:
SNS-101 is a conditionally active, human monoclonal IgG1 antibody, designed to selectively block the immune checkpoint VISTA in the tumor microenvironment, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Lead Product(s): SNS-101,Cemiplimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Regeneron Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 27, 2023
Lead Product(s) : SNS-101,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SNS-101 is a conditionally active, human monoclonal IgG1 antibody, designed to selectively block the immune checkpoint VISTA in the tumor microenvironment, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 27, 2023
Details:
SNS-101 is a conditionally active, human monoclonal IgG1 antibody, designed to selectively block the immune checkpoint VISTA in the tumor microenvironment, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Lead Product(s): SNS-101,Cemiplimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 01, 2023
Lead Product(s) : SNS-101,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SNS-101 is a conditionally active, human monoclonal IgG1 antibody, designed to selectively block the immune checkpoint VISTA in the tumor microenvironment, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 01, 2023
Details:
SNS-101 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): SNS-101
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Regeneron Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 18, 2023
Lead Product(s) : SNS-101
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SNS-101 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 18, 2023
Details:
SNS-101 is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 addresses the problems by binding only in the low-pH tumor microenvironment.
Lead Product(s): SNS-101
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 20, 2023
Lead Product(s) : SNS-101
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SNS-101 is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 addresses the problems by binding only in the low-pH tumor microenviro...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 20, 2023
Details:
SNS-101 is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 addresses the problems by binding only in the low-pH tumor microenvironment.
Lead Product(s): SNS-101
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 21, 2023
Lead Product(s) : SNS-101
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SNS-101 is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 addresses the problems by binding only in the low-pH tumor microenviro...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 21, 2023
Details:
SNS-103 is a conditionally active, monoclonal antibody targeting ENTPDase1 (CD39), an enzyme commonly upregulated by tumors and involved in the conversion of ATP into immunosuppressive adenosine in the tumor microenvironment.
Lead Product(s): SNS-103
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 14, 2023
Lead Product(s) : SNS-103
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SNS-103 is a conditionally active, monoclonal antibody targeting ENTPDase1 (CD39), an enzyme commonly upregulated by tumors and involved in the conversion of ATP into immunosuppressive adenosine in the tumor microenvironment.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 14, 2023
Details:
SNS-101 is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 addresses the problems by binding only in the low-pH tumor microenvironment.
Lead Product(s): SNS-101
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2023
Lead Product(s) : SNS-101
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SNS-101 is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 addresses the problems by binding only in the low-pH tumor microenviro...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 14, 2023
Details:
Under the terms of the CRADA, Sensei will collaborate with the NCI to expand the development of SNS-101, a conditionally active, pH-selective VISTA-blocking antibody and to assess the mechanism of action of SNS-101 in combination with novel therapeutic modalities.
Lead Product(s): SNS-101,Cemiplimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Antibody, Unconjugated
Sponsor: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 06, 2023
Lead Product(s) : SNS-101,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the CRADA, Sensei will collaborate with the NCI to expand the development of SNS-101, a conditionally active, pH-selective VISTA-blocking antibody and to assess the mechanism of action of SNS-101 in combination with novel therapeutic m...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
February 06, 2023
Details:
The supply agreement supports the evaluation of SNS-101, a conditionally active VISTA-blocking antibody, in combination with Libtayo® in a Phase 1/2 trial in solid tumors.
Lead Product(s): SNS-101,Cemiplimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Antibody, Unconjugated
Recipient: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2023
Lead Product(s) : SNS-101,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : The supply agreement supports the evaluation of SNS-101, a conditionally active VISTA-blocking antibody, in combination with Libtayo® in a Phase 1/2 trial in solid tumors.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
January 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
